234 related articles for article (PubMed ID: 37386139)
81. Gastric Cancer CAR T-cell Target Antigen ID'd.
Cancer Discov; 2021 Dec; 11(12):2954. PubMed ID: 34642170
[TBL] [Abstract][Full Text] [Related]
82. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications.
Qian S; Villarejo-Campos P; García-Olmo D
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768570
[TBL] [Abstract][Full Text] [Related]
83. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
84. Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor.
Wang Y; Gao Y; Niu C; Wang B; Zhao S; Roex G; Qian J; Qie J; Chen L; Yi C; Anguille S; Liu J; Luo F; Chu Y
Cancer Immunol Immunother; 2022 Nov; 71(11):2801-2814. PubMed ID: 35441325
[TBL] [Abstract][Full Text] [Related]
85. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene.
Yuan W; Chen J; Cao Y; Yang L; Shen L; Bian Q; Bin S; Li P; Cao J; Fang H; Gu H; Li H
J Gene Med; 2018 Jul; 20(7-8):e3027. PubMed ID: 29851200
[TBL] [Abstract][Full Text] [Related]
86. NR4A transcription factors limit CAR T cell function in solid tumours.
Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
[TBL] [Abstract][Full Text] [Related]
87. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
88. A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function.
Lange S; Sand LGL; Bell M; Patil SL; Langfitt D; Gottschalk S
Cancer Discov; 2021 Jul; 11(7):1661-1671. PubMed ID: 33563660
[TBL] [Abstract][Full Text] [Related]
89. CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.
Li H; Zhou X; Wang G; Hua D; Li S; Xu T; Dong M; Cui X; Yang X; Wu Y; Cai M; Liao X; Zhang T; Yang Z; Du Y; Li X
J Clin Endocrinol Metab; 2022 Mar; 107(4):1110-1126. PubMed ID: 34751400
[TBL] [Abstract][Full Text] [Related]
90. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
91. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
92. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
93. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
94. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
95. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
[TBL] [Abstract][Full Text] [Related]
96. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
97. Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment.
Lewis CR; Dadgar N; Yellin SA; Donnenberg VS; Donnenberg AD; Bartlett DL; Allen CJ; Wagner PL
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894473
[TBL] [Abstract][Full Text] [Related]
98. Surficial nano-deposition locoregionally yielding bactericidal super CAR-macrophages expedites periprosthetic osseointegration.
Li Z; Zhang S; Fu Z; Liu Y; Man Z; Shi C; Tang C; Chen C; Chai Q; Yang Z; Zhang J; Zhao X; Xu H; Han M; Wang Y; Liao Z; Yu G; Shi B; Zhao K; Li W; Jiang X
Sci Adv; 2023 Jun; 9(22):eadg3365. PubMed ID: 37256944
[TBL] [Abstract][Full Text] [Related]
99. Chimeric antigen receptor macrophages activated through TLR4 or IFN-γ receptors suppress breast cancer growth by targeting VEGFR2.
Duan Z; Li Z; Wang Z; Chen C; Luo Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3243-3257. PubMed ID: 37438548
[TBL] [Abstract][Full Text] [Related]
100. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy.
Yang Z; Liu Y; Zhao K; Jing W; Gao L; Dong X; Wang Y; Han M; Shi C; Tang C; Sun P; Zhang R; Fu Z; Zhang J; Zhu D; Chen C; Jiang X
J Control Release; 2023 Aug; 360():718-733. PubMed ID: 37451547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
